That's a lot of positive regulatory news to pack into a single year, so it makes sense that Regeneron's stock was trading at a fresh 52-week high in the summer months. That brings us to the second half of the year, which is when the news …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …
Shares in Regeneron Pharmaceuticals Inc. lost a third of their value in the stock market yesterday after the company disclosed that unforeseen side effects of its drug for the treatment of Lou Gherig's Disease would force the …
Brian Foley, an executive compensation consultant at White Plains-based Brian Foley & Co., said the astronomical compensation package coincided with pyrotechnics by Regeneron stock. "It's a very successful company and you've …
so that Sanofi may sell a small percentage of the Regeneron common stock it owns to fund a portion of the cemiplimab and dupilumab development expansion. This waiver will allow Sanofi to sell in private transactions to Regeneron up to …
... on Regeneron Pharmaceuticals (REGN) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Mar 16, 2018 $380 covered call for a net debit in the $362.68 area. That is also the break-even stock price for the …
Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create ... The second split that needs to take place is Regeneron Pharmaceuticals Inc. (REGN), which trades around $298 per share. That share …
so that Sanofi may sell a small percentage of the Regeneron common stock it owns to fund a portion of the …